Q3 2024 EPS Estimates for BriaCell Therapeutics Corp. (NASDAQ:BCTX) Lowered by HC Wainwright

BriaCell Therapeutics Corp. (NASDAQ:BCTX) – HC Wainwright reduced their Q3 2024 earnings per share (EPS) estimates for shares of BriaCell Therapeutics in a research note issued on Tuesday, April 9th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.55) per share for the quarter, down from their prior estimate of ($0.20). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for BriaCell Therapeutics’ Q4 2024 earnings at ($0.46) EPS, FY2024 earnings at ($1.39) EPS, FY2025 earnings at ($1.40) EPS, FY2026 earnings at ($1.64) EPS, FY2027 earnings at ($1.45) EPS and FY2028 earnings at ($1.11) EPS.

BriaCell Therapeutics Stock Performance

BCTX stock opened at $2.49 on Friday. The company has a market capitalization of $39.79 million, a price-to-earnings ratio of -1.48 and a beta of 1.02. BriaCell Therapeutics has a fifty-two week low of $2.19 and a fifty-two week high of $7.67. The stock has a fifty day moving average of $3.12 and a 200-day moving average of $4.18.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its quarterly earnings results on Monday, March 18th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.51).

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in BCTX. National Bank of Canada FI raised its holdings in shares of BriaCell Therapeutics by 200.0% in the 4th quarter. National Bank of Canada FI now owns 7,500 shares of the company’s stock valued at $40,000 after acquiring an additional 5,000 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of BriaCell Therapeutics in the 1st quarter valued at about $77,000. Virtu Financial LLC purchased a new stake in shares of BriaCell Therapeutics in the 2nd quarter valued at about $60,000. Natixis purchased a new position in shares of BriaCell Therapeutics during the 4th quarter valued at about $56,000. Finally, HighTower Advisors LLC purchased a new position in shares of BriaCell Therapeutics during the 1st quarter valued at about $107,000. Institutional investors own 15.42% of the company’s stock.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.